Skip to content Skip to footer
Subscribe Now
Viewpoints_Ying Huang
VIEWPOINTS

PharmaShots Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends' collaboration with Janssen. Shots: The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were recently presented at the 62nd ASH Meeting The…
February 25, 2021

Read more

Viewpoints_Andreas Harstrick
VIEWPOINTS

PharmaShots Interview: Affimed’s Andreas Harstrick Shares Insight on AFM13 and its Data Presented at ASH 2020

In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two…
February 10, 2021

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]